Upstream Bio
Biotechnology Research
890 Winter St
66 employees
- Employees
- 66
- Contacts
- 4
- Emails
- 4
- Phones
- 3
Upstream Bio Overview
- Headquarters
- 890 Winter St
- Website
- www.upstreambio.com
- Industry
- Biotechnology Research
- Employees
- 66
- Founded
- 2021
- Funding
- 200.0M
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
About Upstream Bio
We are advancing verekitug, a clinical-stage monoclonal antibody targeting an upstream driver of inflammatory response. Our experienced team is committed to leveraging verekitug’s unique mechanism of action to improve the treatment options for millions of patients living with severe inflammatory diseases.
Upstream Bio Contact Details
- People in AeroLeads
- 4
- With contact data
- 4
- Email contacts
- 4
- 100.0% coverage
- Phone contacts
- 3
- 75.0% coverage
Upstream Bio Org Chart
Sample employees and titles| Name | Title | Location | Contact |
|---|---|---|---|
| Ron Renaud | President & CEO - Kailera Therapeutics | Waltham, Massachusetts, United States |
Email
Phone
|
| Rebecca Nuzzo | United States |
Email
|
|
| Stacy Petti Price | Chief Technology & Manufacturing | Greater Boston, United States |
Email
Phone
|
| Michael Gray | Chief Financial and Chief Operating | Waltham, Massachusetts, United States |
Email
Phone
|
Employees by Management Level
Executive
3 profiles
Compare Similar Companies to Upstream Bio
Immatics
Biotechnology Research
Scholar Rock
Biotechnology
Kailera Therapeutics
Biotechnology Research
CAMP4 Therapeutics
Biotechnology Research
City Therapeutics
Biotechnology Research
Purespring Therapeutics
Biotechnology Research
GC Therapeutics
Biotechnology Research
Gritstone bio
Biotechnology Research
Judo Bio
Biotechnology Research
Galmed Pharmaceuticals Ltd.
Pharmaceutical Manufacturing